Appointment furthers ASCPT's commitment to diversity, equity, and inclusion

SOURCE: Gilead Sciences

DESCRIPTION:

We’re proud to share that Mark Dresser, Gilead’s Senior Vice President of Biomarker Sciences and Clinical Pharmacology, has been elected President of the American Society for Clinical Pharmacology & Therapeutics (ASCPT). As the first openly LGBTQ+ president in ASCPT’s 122-year history, Mark is an exemplary leader for our industry – and one who advocates for LGBTQ+ equality in STEM and furthers inclusion within the scientific community.

About Gilead Sciences

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.

Originally Published by Gilead Sciences

Tweet me: .@GileadSciences is proud to announce Mark Dresser, VP of Biomarker Sciences and Clinical Parmacology has been elected President of the ASCPT. Find out more here: https://bit.ly/3s90VSY

KEYWORDS: NASDAQ: GILD, ASCPT, Gilead Sciences